Vipera berus venom toxins

Vipera berus venom toxins represent a complex pharmacological mixture of proteins and peptides produced by the common European adder. The venom's primary constituents include phospholipase A2 (PLA2), snake venom metalloproteinases (SVMPs), and serine proteinases, which act synergistically to disrupt physiological processes [PubMed: 25660107, PubMed: 16023278]. PLA2 enzymes are responsible for cell membrane degradation and inflammatory mediator release, contributing to the characteristic pain and swelling seen in victims [UniProt: P00613]. SVMPs target the vascular endothelium and extracellular matrix, leading to significant hemorrhage and local tissue edema by degrading basement membrane proteins [PubMed: 16023278]. Serine proteinases within the venom can interfere with the coagulation cascade, potentially causing systemic coagulopathy [PubMed: 25660107]. Clinically, these toxins are the direct targets of antivenom therapy, where specific immunoglobulin fragments (Fab or F(ab')2) bind and neutralize the venom components to prevent systemic toxicity [Electronic Medicines Compendium: ViperaTab]. Management of envenomation focuses on neutralizing these toxins to mitigate risks of hypotension, thrombocytopenia, and extensive local necrosis [StatPearls: Snake Envenomation]. The variability in venom composition across different geographic regions can influence the severity of the clinical presentation and the efficacy of specific antivenoms [PubMed: 25660107].

Other names

Common European adder venomVipera berus toxinsEuropean viper venom

Neutralization of toxic enzymatic and non-enzymatic proteins via antibody-mediated binding (Fab or F(ab')2 fragments), which prevents the toxins from interacting with their physiological targets such as cell membranes, coagulation factors, and the vascular endothelium.